Shire Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) in Adults with Binge Eating Disorder
Company Plans to Conduct Additional Analyses of These Preliminary Data
PHILADELPHIA, April 26, 2012 /PRNewswire/ —
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder. Following discussions with the US Food and Drug Administration (FDA), Shire plans to conduct additional larger studies to confirm the validity of the findings.
Read more, click here.